Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) Inc, formerly known as Ketamine One, has announced the successful facilitation of its first intravenous (IV) ketamine treatment to a patient at the Victoria Wellness (VW) Mental Health Residential and Addiction Treatment Centre in Ontario through its collaboration with iHealthOX.
The Vancouver, British Columbia-based company noted that VW is one of the first in-patient facilities to offer ketamine-assisted therapy in Canada. It said it expects the collaboration between VW, iHealthOX and itself to experience an increase in the number of patients treated via IV ketamine infusions.
"The success of our first IV ketamine treatment in Canada in collaboration with VW and iHealthOX and Wellbeing is encouraged that ketamine-based treatments for mental health are becoming more commonplace,” Wellbeing interim CEO Adam Deffett said in a statement.
READ: Ketamine One becomes exclusive provider of ketamine treatment to Victoria Wellness
The VW centre is a residential rehabilitation facility and mental health clinic focused on treating anxiety, depression, and post-traumatic stress disorder (PTSD) by offering personalized therapy treatment programs.
Wellness said it and VW have launched a first-class, best practice-based, six-week in-patient Ketamine Integrated Therapy Experience (KITE) program, with the first three weeks structured to offer clients a unique opportunity to benefit from fast-acting and medically supervised IV ketamine administration. This process is expected to help combat long-standing and prescription-resistant mental health conditions such as depression and PTSD, the company said.
Wellness noted that its previously announced arrangement with iHealthOX helped to make the first IV ketamine treatment possible. iHealthOX was created to provide patients with a customized digital tool specifically for mental health. Patients have access to live coaching sessions, as well as options for one-on-one therapy, evidence-based educational material, and 24/7 emergency support.
The iHealthOX platform will be available to patients in both desktop and mobile versions, thereby extending the company's services beyond its clinic locations.
“The company has always wanted to make a positive and significant impact on mental health and this brings us one step closer,” Deffett added.
“Achievements like this, exemplify why Wellbeing continues to work hard to make a difference in the mental health realm.”
Wellbeing Digital Sciences (NEO:MEDI.AQN, OTCQB:KONEF) is an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics, and contract research. Its mission is supported by a network of North American clinics that provide ketamine-assisted therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
Contact the author at stephen.gunnion@proactiveinvestors.com